Topics

Companies Related to "Prexasertib treatment induces homologous recombination deficiency synergizes with" [Most Relevant Company Matches] RSS

13:47 EDT 4th April 2020 | BioPortfolio

Here are the most relevant search results for "Prexasertib treatment induces homologous recombination deficiency synergizes with" found in our extensive corporate database of over 50,000 company records.

Showing "Prexasertib treatment induces homologous recombination deficiency synergizes with" Companies 1–25 of 3,500+

Relevant

AMAG Pharmaceuticals, Inc.


Lumos Pharma, Inc.

Lumos Pharma, Inc. is a clinical stage biopharmaceutical company focused on development and commercialization of therapeutics for rare and neglected diseases. Lumos Pharma was founded and is led by a management team with longstanding experience in rare disease drug development and is funded by leading healthcare investors, including Deerfield, NEA, Clarus,...

Diagnostica & Analys Service AB

Haemophilia caused by Factor VIII - or Factor IX deficiency and von Willebrand disease have long been possible to diagnose, but with some difficulties for the latter. In the mid 1970's Antithrombin III (ATIII) was suspected of being an important cause of thrombosis as patients with this deficiency often suffered from thrombotic complications and had a poor prognosis with Disseminated Intravascular...


AlphaNet

Alpha-1 Antitrypsin Deficiency is a leading genetic killer of adults and a leading cause of liver transplants in children. It is estimated that 20 million Americans are undetected carriers of the Alpha-1 gene and may be at risk for lung and/or liver disease. Only 10 percent of the estimated 100,000 with severe deficiency of Alpha-1 have been diagnosed.

Rocket Pharmaceuticals, Inc.

Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) (“Rocket”) is an emerging, clinical-stage biotechnology company focused on developing first-in-class gene therapy treatment options for rare, undertreated diseases. Rocket’s multi-platform development approach applies the well-established lentiviral vector (LVV) and adeno-associated viral vector (AA...

KAI Pharmaceuticals, Inc.

KAI Pharmaceuticals is a biology-based product-driven pharmaceutical company developing a new class of therapeutics targeting cell-signaling enzymes that affect numerous disease pathways. The company is leveraging its leadership position in protein kinase C (PKC), an important and validated family of kinases, to rapidly advance product candidates into human clinical trials.KAI is developing therap...

Rocket Pharmaceuticals, Ltd.

Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) (“Rocket”) is an emerging, clinical-stage biotechnology company focused on developing first-in-class gene therapy treatment options for rare, undertreated diseases. Rocket’s multi-platform development approach applies the well-established lentiviral vector (LVV) and adeno-associated viral vector (A...

Cellectis SA

Cellectis is the worldwide leader in the research, development and commercialization of rational genome engineering technologies. Cellectis proprietary technologies and platform are based upon a naturally occurring class of DNA endonucleases, the Meganucleases and DNA recombination.The DNA recognition and function of Meganucleases can be used to target a unique DNA break at a specific location wit...

Viral Genetics

Viral Genetics is developing immune-based therapies for the treatment of HIV/AIDS and other infectious, autoimmune, and immunological deficiency disorders. The Company’s primary product candidate is VGV-1, an investigational therapy for the treatment of HIV/AIDS that has demonstrated an antiviral effect in clinical trials with an apparent immunological mechanism of action. VGV-1 is a suspension ...

GTC Biotherapeutics

GTC Biotherapeutics develops, produces, and commercializes therapeutic proteins using transgenic animal technology. ATryn®, recombinant human antithrombin, is the first transgenically produced therapeutic protein approved anywhere in the world, having recently been approved by the European Commission (EMEA) for the prophylactic treatment of deep vein thrombosis in patients with hereditary antith...

Cytochroma Inc

Cytochroma Inc. is an integrated specialty pharmaceutical company engaged in the development and commercialization of proprietary products to treat and prevent the clinical consequences of diseases and disorders related to vitamin D deficiency. The company has an advanced portfolio of new products targeting vitamin D deficiency and secondary hyperparathyroidism in patients with moderate to severe ...

Arno Therapeutics, Inc.

Arno Therapeutics, Inc. is a clinical-stage biopharmaceutical company that develops and commercializes innovative products for the treatment of cancer patients. In addition to AR-67, Arno's lead clinical compound is AR-12, a potentially first-in-class, orally available PDK1 inhibitor that blocks the PI3K/Akt pathway and induces autophagy and the endoplasmi...

Immune Deficiency Foundation

Digvijaya Management Consultants

Knowledge in any form is the single most vital factor that powers the world towards progress & prosperity. The same knowledge is manifested in diverse forms, which synergizes to make this world a better place to live in. Health Care Industry specially the Pharmaceutical Industry is an invaluable sphere on whose rapid strides depends the world population's well being. The Pharma sector hence thrive...

TearScience

Headquartered in Morrisville, North Carolina, TearScience has pioneered devices that provide significant clinical improvement in the treatment of evaporative dry eye. Of the more than 100 million dry eye sufferers worldwide, approximately 65 percent have evaporative dry eye, which is caused by meibomian gland dysfunction and a lipid deficiency of the eyeâ...

Columbia Laboratories, Inc.

Columbia Laboratories, Inc. is focused on developing products that utilize its novel bioadhesive drug delivery technologies to optimize drug delivery in a controlled, sustained manner. The Company's strategy is to fund new development projects through proof of concept, then partner for later-stage clinical development and commercialization. CRINONE® 8% ...

TearScience, Inc.

Headquartered in Morrisville, North Carolina, TearScience has pioneered devices that provide significant clinical improvement in the treatment of evaporative dry eye. Of the more than 100 million dry eye sufferers worldwide, approximately 65 percent have evaporative dry eye, which is caused by meibomian gland dysfunction and a lipid deficiency of the eyeâ...

TearScience, Inc. and The Herzig Eye Institute

Headquartered in Morrisville, North Carolina, TearScience has pioneered devices that provide significant clinical improvement in the treatment of evaporative dry eye. Of the more than 100 million dry eye sufferers worldwide, approximately 65 percent have evaporative dry eye, which is caused by meibomian gland dysfunction and a lipid deficiency of the eyeâ...

Shield Therapeutics

Shield, founded in 2008, is an independent specialty pharmaceutical company focused on the development and commercialisation of late-stage, mineral-derived hospital pharmaceuticals which address areas of high unmet medical need. Shield is currently preparing to undertake a global pivotal Phase III study of its lead asset, ST10-021, for the treatment of iron deficiency anaemia associated with i...

Celladon Corporation

Celladon Corporation, based in La Jolla, California, was launched in October 2004 as a privately held biotechnology company founded with the goal of becoming the leader in developing molecular therapies for the treatment of heart failure. The company’s products target the key enzyme deficiency in advanced heart failure, SERCA2a, which regulates calcium ...

Probably Relevant

Raptor Pharmaceuticals Corp.

Raptor Pharmaceutical Corp. ("the Company") is dedicated to speeding the delivery of new treatment options to patients by working to improve existing therapeutics through the application of highly specialized drug targeting platforms and formulation expertise. The Company focuses on underserved patient populations where it can have the greatest potential impact and currently has product candidates...

The American Association of Clinical Endocrinologists

The American Association of Clinical Endocrinologists (AACE) represents more than 6,500 endocrinologists in the United States and abroad. AACE is the largest association of clinical endocrinologists in the world. The majority of AACE members are certified in Endocrinology and Metabolism and concentrate on the treatment of patients with endocrine and metabo...

TheAmerican Association of Clinical Endocrinologists (AACE)

The American Association of Clinical Endocrinologists (AACE) represents more than 6,500 endocrinologists in the United States and abroad. AACE is the largest association of clinical endocrinologists in the world. The majority of AACE members are certified in Endocrinology, Diabetes and Metabolism and concentrate on the treatment of patients with endocrine ...

The American Association of Clinical Endocrinologists (AACE)

The American Association of Clinical Endocrinologists (AACE) represents more than 6,500 endocrinologists in the United States and abroad. AACE is the largest association of clinical endocrinologists in the world. The majority of AACE members are certified in endocrinology, diabetes and metabolism and concentrate on the treatment of patients with endocrine ...

Gilead Sciences

Gilead Sciences, Inc. is an independent biopharmaceutical company that seeks to provide accelerated solutions forpatients and the people who care for them. The Company discovers, develops and commercializes proprietary therapeutics for important viral diseases, including the currently marketed product VISTIDE-Registered Trademark- (cidofovir injection) for the treatment of cytomegalovirus ("CMV") ...


More From BioPortfolio on "Prexasertib treatment induces homologous recombination deficiency synergizes with"

Quick Search

Corporate Database Quicklinks